The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
PLUVICTO (Novartis Pharmaceuticals Australia Pty Ltd)
Product name
PLUVICTO
Date registered
Evaluation commenced
Decision date
Approval time
197 (255 working days)
Active ingredients
lutetium (177Lu) vipivotide tetraxetan
Registration type
NCE/NBE
Indication
PLUVICTO is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.